Michael Hai Luu Nguyen, Ph.D.’s Post

View profile for Michael Hai Luu Nguyen, Ph.D., graphic

LNP Guy🧬 | BD Manager at Helix Biotech, PhD

💲Notable RNA deals in March and April 💲 These deals underscore the significance of RNA therapeutics and the delivery systems that ensure their precise targeting and efficacy. Headlined by the acquisition of Cardior Pharmaceuticals by Novo Nordisk for $1.1b USD. Cardior Pharmaceutical technology specializes in targeting abnormal levels of microRNA. Capstan Therapeutics raised an impressive $175m in their oversubscribed Series B. Capstan Therapeutics is looking to advance their CAR-T cell candidate and their targeted LNP pipelines. Regulus Therapeutics recently announced an oversubscribed $100m private placement of equity. They are focused on their pipeline candidates which target microRNAs. Orgenesis Inc. secured a $2.3m private investment and is expected to secure further payments. Orgenesis is a biotech focused on cell and gene therapies, aiming to provide affordable healthcare to patients. ----- Century Therapeutics, Inc raised $60m in private investments and used these funds to acquire Clade Therapeutics. With this move, Century adds to their allogeneic cell therapies. TuHURA Biosciences, Inc. received $31m subscribed financing and have entered into a definitive merger agreement with Kintara Therapeutics, Inc. NASDAQ: KTRA. GenEditBio Limited recently announced their $10m USD Pre-A+ funding round, their third funding round since 2021. The additional funds will be used to further their genome-editing technology platforms, e.g. LNPs and ePDVs. ARCA biopharma and Oruka Therapeutics announced their merger agreement earlier this month. They will look to advance Oruka's pipeline of potentially best-in-class biologics for the treatment of chronic skin diseases. ----- Deals pulled from Beacon Intelligence database. 🌟 Enjoying my content? Repost and follow Michael Hai Luu Nguyen, Ph.D. & Helix Biotech, Inc. for more! 🌟 #RNA #mRNA #RNAtherapeutics #LNPs #LNP #Helixbiotech #investors #deals #funding #biotech #pharma

To view or add a comment, sign in

Explore topics